Emerging immunotherapeutic strategies targeting telomerases in genitouiinark tumors

被引：12

作者：

Carrozza, Francesco ^{[1
]}

Santoni, Matteo ^{[2
]}

Piva, Francesco ^{[3
]}

Cheng, Liang ^{[4
]}

Lopez-Beltran, Antonio ^{[5
]}

Scarpelli, Marina ^{[6
]}

Montironi, Rodolfo ^{[6
]}

Battelli, Nicola ^{[2
]}

Tamberi, Stefano ^{[1
]}

机构：

[1] City Hosp, Oncol Unit, Faenza, Italy

[2] Macerata Hosp, Oncol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy

[3] Polytech Univ Marche, Dept Specialist Clin & Odontostomatol Sci, Ancona, Italy

[4] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[5] Cordoba Univ, Sch Med, Dept Surg, Cordoba, Spain

[6] Polytech Univ Marche Reg, Sch Med, United Hosp, Sect Pathol Anat, Ancona, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2018年 / 131卷

关键词：

Bladder cancer; Immunotherapy; Prostate cancer; Renal cancer; Telomerases; RENAL-CELL CARCINOMA; TERT PROMOTER MUTATIONS; BLADDER-CANCER; PROSTATE-CANCER; PEPTIDE VACCINE; MESSENGER-RNA; HTERT; INHIBITION; GROWTH; LENGTH;

D O I：

10.1016/j.critrevonc.2018.07.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Telomerase activity and telomere length are essential for the pathogenesis of several human diseases, including genitourinary tumors. Telomerase constitutes a complex system that includes human telomerase reverse transcriptase (hTERT), human telomerase RNA component (hTR) and telomerase associated protein 1 (TEP1), which are overexpressed in tumor cells compared to normal cells and are involved in the carcinogenesis and progression of renal cell carcinoma (RCC), bladder (BC) and prostate cancer (PCa). In addition, telomerase degraded peptide fragments expressed on the surface of tumor cells lead to their recognition by immune cells. On this scenario, in vitro and in vivo studies have shown effective anti-tumor activity of hTERT-tailored strategies in genitourinary tumors, including active immunotherapy with hTERT-peptide vaccines and passive immunotherapy with hTERT-transduced T cell infusion. This review emphasizes the role of telomerase in the carcinogenesis and progression of genitourinary tumors, thus underlying the potential of emerging telomerase-tailored immunotherapies in these patients.

引用

页码：1 / 6

页数：6

共 60 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA [J].

Bai, Yun ;

Kan, Shifeng ;

Zhou, Shixin ;

Wang, Yuting ;

Xu, Jun ;

Cooke, John P. ;

Wen, Jinhua ;

Deng, Hongkui .

CELL DISCOVERY, 2015, 1

[3] Systematic analysis of telomere length and somatic alterations in 31 cancer types [J].

Barthel, Floris P. ;

Wei, Wei ;

Tang, Ming ;

Martinez-Ledesma, Emmanuel ;

Hu, Xin ;

Amin, Samirkumar B. ;

Akdemir, Kadir C. ;

Seth, Sahil ;

Song, Xingzhi ;

Wang, Qianghu ;

Lichtenberg, Tara ;

Hu, Jian ;

Zhang, Jianhua ;

Zheng, Siyuan ;

Verhaak, Roel G. W. .

NATURE GENETICS, 2017, 49 (03) :349-357

[4] Telomeres and Telomerase: The Means to the End (Nobel Lecture) [J].

Blackburn, Elizabeth H. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (41) :7405-7421

[5] Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts [J].

Brems-Eskildsen, Anne Sofie ;

Zieger, Karsten ;

Toldbod, Helle ;

Holcomb, Cherie ;

Higuchi, Russell ;

Mansilla, Francisco ;

Munksgaard, Pia P. ;

Borre, Michael ;

Orntoft, Torben F. ;

Dyrskjot, Lars .

BMC CANCER, 2010, 10

[6] Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer [J].

Brunsvig, Paal F. ;

Aamdal, Steinar ;

Gjertsen, Marianne K. ;

Kvalheim, Gunnar ;

Markowski-Grimsrud, Carrie J. ;

Sve, Ingunn ;

Dyrhaug, Marianne ;

Trachsel, Sissel ;

Moller, Mona ;

Eriksen, Jon A. ;

Gaudernack, Gustav .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (12) :1553-1564

[7]

Chen W., 2017, BIOMED RES INT

[8] The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma [J].

Davis, Caleb F. ;

Ricketts, Christopher J. ;

Wang, Min ;

Yang, Lixing ;

Cherniack, Andrew D. ;

Shen, Hui ;

Buhay, Christian ;

Kang, Hyojin ;

Kim, Sang Cheol ;

Fahey, Catherine C. ;

Hacker, Kathryn E. ;

Bhanot, Gyan ;

Gordenin, Dmitry A. ;

Chu, Andy ;

Gunaratne, Preethi H. ;

Biehl, Michael ;

Seth, Sahil ;

Kaipparettu, Benny A. ;

Bristow, Christopher A. ;

Donehower, Lawrence A. ;

Wallen, Eric M. ;

Smith, Angela B. ;

Tickoo, Satish K. ;

Tamboli, Pheroze ;

Reuter, Victor ;

Schmidt, Laura S. ;

Hsieh, James J. ;

Choueiri, Toni K. ;

Hakimi, A. Ari ;

Chin, Lynda ;

Meyerson, Matthew ;

Kucherlapati, Raju ;

Park, Woong-Yang ;

Robertson, A. Gordon ;

Laird, Peter W. ;

Henske, Elizabeth P. ;

Kwiatkowski, David J. ;

Park, Peter J. ;

Morgan, Margaret ;

Shuch, Brian ;

Muzny, Donna ;

Wheeler, David A. ;

Linehan, W. Marston ;

Gibbs, Richard A. ;

Rathmell, W. Kimryn ;

Creighton, Chad J. ;

Signoretti, Sabina ;

Seiler, Michael ;

Chao, Hsu ;

Dahdouli, Mike .

CANCER CELL, 2014, 26 (03) :319-330

[9] Association of Human Telomerase Reverse Transcriptase Gene Polymorphisms, Serum Levels, and Telomere Length With Renal Cell Carcinoma Risk and Pathology [J].

de Martino, Michela ;

Taus, Christopher ;

Lucca, Ilaria ;

Hofbauer, Sebastian L. ;

Haitel, Andrea ;

Shariat, Shahrokh F. ;

Klatte, Tobias .

MOLECULAR CARCINOGENESIS, 2016, 55 (10) :1458-1466

[10] In vivo inhibition of lung cancer by GRN163L:: A novel human telomerase inhibitor [J].

Dikmen, ZG ;

Gellert, GC ;

Jackson, S ;

Gryaznov, S ;

Tressler, R ;

Dogan, P ;

Wright, WE ;

Shay, JW .

CANCER RESEARCH, 2005, 65 (17) :7866-7873

← 1 2 3 4 5 6 →